About

Vast experience: check. Deep expertise: check. Easy accessibility: check. After decades of investing from offices in the most important centers of biotechnology worldwide, Abingworth offers entrepreneurs an unmatched combination of all three of these key attributes.

LDNBOSSFO
Watch The Abingworth Edge

ABINGWORTH'S TRANSATLANTIC REACH

With offices in the world's key biotech centres, we support entrepreneurs in both the US and Europe.

We benefit from our transatlantic approach through a broader understanding of competitive geographies, expertise in many different capital markets, access to a larger pool of management talent and wider scientific networks.

Abingworth Bioventures82021Abingworth Bioventures72017Abingworth ClinicalCo-Development2016Abingworth BioventuresVI2012Abingworth BioventuresV2008Abingworth BioventuresV2007AbingworthBioEquities2005Abingworth BioventuresIV2003AbingworthBioEquities2005Abingworth BioventuresIV2003Abingworth BioventuresIIa2002Abingworth BioventuresIII2001Abingworth BioventuresII1997AbingworthBioventures1992Biotechnology VentureFund1987
2021Abingworth Bioventures 8
2017Abingworth Bioventures 7
2016Abingworth Clinical Co-Development
2012Abingworth Bioventures VI
2008Abingworth Bioventures V Growth Equity
2007Abingworth Bioventures V
2005Abingworth BioEquities
2003Abingworth Bioventures IV
2002Abingworth Bioventures IIa
2001Abingworth Bioventures III
1997Abingworth Bioventures II
1992Abingworth Bioventures
1987Biotechnology Venture Fund
ABVII, III and IV are in liquidation.
BVF, ABV and ABVIIa are already liquidated.

13 LIFE SCIENCE FUNDS

Abingworth has raised 13 funds dedicated to investing in life sciences and healthcare. Our most recent, Abingworth Bioventures 8 and Abingworth Clinical Co-Development Fund, raised $465 million and $108 million respectively and are actively investing.

Venture Funds

Our venture funds invest across our broad strategic areas of venture capital, clinical co-development, VIPEs and public markets. They focus primarily on private companies but invest a percentage of their value in public companies.

List all funds
Close

Abingworth Films

Currently Watching
CRISPR Tx
Currently Watching
GenSight
Currently Watching
SFJ II (Eisai)
Currently Watching
Vaxcyte
Currently Watching
Verona
Currently Watching
Wilson Therapeutics
Currently Watching
COVID 19 Expert View: Genghis Lloyd-Harris Speaks with Moncef Slaoui, Chief Scientific Advisor for OWS
Currently Watching
COVID 19 Expert View: Genghis Lloyd-Harris Speaks with Adrian Hayday, Peter Gorer Dept of Immunobiology and Francis Crick Institute London